<- Go Home
Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Market Cap
$248.9M
Volume
1.8M
Cash and Equivalents
$39.6M
EBITDA
-$125.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$81.2M
Profit Margin
1284.83%
52 Week High
$2.46
52 Week Low
$0.91
Dividend
N/A
Price / Book Value
1.38
Price / Earnings
-1.96
Price / Tangible Book Value
1.38
Enterprise Value
$150.8M
Enterprise Value / EBITDA
-1.36
Operating Income
-$138.3M
Return on Equity
55.50%
Return on Assets
-25.29
Cash and Short Term Investments
$174.8M
Debt
$76.8M
Equity
$179.7M
Revenue
$6.3M
Unlevered FCF
-$50.1M
Sector
Biotechnology
Category
N/A